Pricing Log in Create free account

Palisade Bio, Inc. (PALI) vs Prelude Therapeutics Incorporated (PRLD)

Palisade Bio, Inc. and Prelude Therapeutics Incorporated are both Biotechnology companies. Palisade Bio, Inc. and Prelude Therapeutics Incorporated are of similar size ($268.4M and $265.0M). Prelude Therapeutics Incorporated has negative trailing earnings, so its P/E is not meaningful; Palisade Bio, Inc. trades at 2.2×. Prelude Therapeutics Incorporated has the higher net margin (−269.8% vs −4,230.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Prelude Therapeutics Incorporated leads on 9 and Palisade Bio, Inc. on 5.

Valuation

Metric PALI PRLD Biotechnology median
P/E 2.18 n/m 8.50
P/S 394.77 14.30 9.71
P/B 2.45 2.40 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 229.61 7.54 9.21
Earnings yield 45.93% (22.39%) (33.15%)
Free cash flow yield (6.11%) (10.39%) (25.50%)

Profitability

Metric PALI PRLD Biotechnology median
Gross margin 95.63% 100.00% 65.16%
Operating margin (4,681.99%) (300.56%) 0.00%
Net margin (4,230.60%) (269.75%) 0.00%
Free cash flow margin (2,409.27%) (148.30%) 0.00%
Return on equity (51.37%) (57.73%) (56.36%)
Return on assets (47.68%) (39.76%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric PALI PRLD Biotechnology median
Revenue growth (TTM) 5,492.59% — 6.02%
EPS growth (last fiscal year) 97.06% 23.21% 30.26%
Revenue growth, 5-year CAGR 72.86% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PALI PRLD Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 24.26 4.07 4.72
Net debt to EBITDA 7.37 1.00 0.96

Dividend

Metric PALI PRLD Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric PALI PRLD Biotechnology median
Market cap 268.38m 264.95m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack